Trendlines, B Braun firm up deal to invest in healthcare incubator
SINGAPORE-LISTED Trendlines Group and Germany-based B Braun have executed a definitive investment and cooperation agreement to jointly invest in Trendlines Medical Singapore (TMS), a platform to invest in and incubate early-stage healthcare companies with a focus on Singapore and the region.
B Braun will take a minority stake of 20.74 per cent in TMS, with Trendlines holding the majority 79.26 per cent interest.
Anna Maria Braun, president of B Braun Asia-Pacific and a member of the B Braun management board, and Boris Hofmann, director of business development of B Braun's Aesculap division, are joining the TMS board of directors. Todd Dollinger, chairman and CEO of Trendlines, is the chairman of TMS.
TMS is Trendlines' first incubator outside of Israel.
B Braun will support the commercialisation of TMS's portfolio companies by providing medtech-related expertise, such as regulations, medical and scientific affairs, and marketing and sales.
Mr Dollinger said in September when the joint investment with B Braun was unveiled, that though its focus is in medtech, TMS will not rule out investing in other tech types.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
DigitalBridge-backed Vantage said to weigh Hong Kong data centres sale
Vietnam delays launch of new stock trading system
Tesla’s plan for affordable cars takes page from Detroit rivals
Meituan to debut in Riyadh as expansion beyond China quickens
Mapletree Industrial Trust to distribute S$13 million of divestment gains over next 4 quarters
K-pop agency Hybe’s internal strife wipes out 1.2 trillion won